Urapidil (hydrochloride)

• UNSPSC Description:

  Urapidil hydrochloride is an orally active α1-adrenoceptor antagonist and 5-HT1A receptor agonist with a pIC50 of 6.13 and 4.38 against α1- and α2-adrenoceptor, respectively. Urapidil hydrochloride shows antihypertensive effect[1][2].

• Target Antigen:

  5-HT Receptor; Adrenergic Receptor

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein;Neuronal Signaling

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Cardiovascular Disease; Endocrinology

• Assay Protocol:

  https://www.medchemexpress.com/urapidil-hydrochloride.html

• Purity:

  99.97

• Solubility:

  DMSO : 14.29 mg/mL (ultrasonic;warming;heat to 60°C)|H2O : 100 mg/mL (ultrasonic)

• Smiles:

  O=C1N(C)C(C=C(NCCCN2CCN(C3=CC=CC=C3OC)CC2)N1C)=O.Cl

• Molecular Weight:

  423.94

• References & Citations:

  [1]Gross, G., G. Hanft, and N. Kolassa, Urapidil and some analogues with hypotensive properties show high affinities for 5-hydroxytryptamine (5-HT) binding sites of the 5-HT1A subtype and for alpha 1-adrenoceptor binding sites. Naunyn Schmiedebergs Arch Pharmacol, 1987. 336(6): p. 597-601.|[2]Buch, J., Urapidil, a dual-acting antihypertensive agent: Current usage considerations. Adv Ther, 2010. 27(7): p. 426-43.|[3]Vanhaesebrouck S, et al. Neonatal transient respiratory depression after maternal urapidil infusion for hypertension. Eur J Pediatr. 2009 Feb;168(2):221-3.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, sealed storage, away from moisture)

• Clinical Information:

  Launched

• CAS Number:

  64887-14-5